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Abstract
Background: A small percentage of all cases of schizophrenia have a childhood onset. The impact on the
individual and family can be devastating. We report the results of genetic analyses from a patient with onset of
visual hallucinations at 5 years, and a subsequent diagnosis at 9 years of schizophrenia, attention deficit
hyperactivity disorder (ADHD) with hyperactivity and impulsivity, and chronic motor tic disorder.
Results: Karyotypic analysis found 45,XX,i(13)(q10) in all cells examined. Alpha satellite FISH of isochromosome 13
revealed a large unsplit centromeric region, interpreted as two centromeres separated by minimal or undetectable
short-arm material or as a single monocentric centromere, indicating that the isochromosome likely formed post-
zygotically by a short arm U-type or centromeric exchange. Characterization of chromosome 13 simple tandem
repeats and Affymetrix whole-genome 6.0 SNP array hybridization found homozygosity for all markers, and the
presence of only a single paternal allele in informative markers, consistent with an isodisomic isochromosome of
paternal origin. Analysis of two chromosome 13 schizophrenia candidate genes, D-amino acid oxidase activator
(DAOA) and 5-hydroxytryptamine (serotonin) receptor 2A (5-HTR2A), failed to identify non-synonymous coding
mutations but did identify homozygous risk polymorphisms.
Conclusions: We report a female patient with childhood-onset schizophrenia, ADHD, and motor tic disorder
associated with an isodisomic isochromosome 13 of paternal origin and a 45,XX,i(13)(q10q10) karyotype. We
examined two potential mechanisms to explain chromosome 13 involvement in the patient’s pathology, including
reduction to homozygosity of a paternal mutation and reduction to homozygosity of a paternal copy number
variation, but were unable to identify any overtly pathogenic abnormality. Future studies may consider whether
epigenetic mechanisms resulting from uniparental disomy (UPD) and the lack of chromosome 13 maternal alleles
lead to the patient’s features.
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Background
Schizophrenia affects approximately 1% of the general
population [1]. While symptoms of the disorder gener-
ally manifest themselves in the late teens or twenties,
they appear before the age of 18 years in approximately
4% of cases [2] and have been reported as early as 3
years [3]. Features of childhood-onset schizophrenia are
typically more severe than found in the adult-onset
form of the disease, and affected children exhibit audi-
tory hallucinations and delusions, accompanied by a flat-
tened affect, deficits of speech and language, motor
development, attention and memory, and social fluency
as well as reduced cognitive performance [4]. Long-term
outcomes for children with schizophrenia may be worse
than adult-onset cases, with continued risk of morbidity
[4].
Adult-onset schizophrenia is considered a neurodeve-
lopmental disorder resulting from the interaction of a
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siderable effort has been put forth to identify genes
associated with schizophrenia, and multiple predisposing
genes have been identified, including CHRNA7 [5],
DAOA [6], COMT, DTNBP1, NRG1, DISC1, GRM3, and
PRODH [7]. In the last several years, Genome-Wide
Association Studies (GWAS) have led to many newly
identified schizophrenia susceptibility loci, including the
major histocompatibility complex, CACNA1C,t h e
ITIH3-ITIH4 region, ZNF804A, PLAA, ANK3,a n d
others [8-21]. Challenges to these studies include mod-
est effects of individual variations, as well as lack of
interstudy reproducibility. Genomic copy number varia-
tion (CNV) studies have revealed several regions of
duplication/deletion, including a recurrent deletion of
22q11.2 and microdeletions of 1q21.1, 15q11.2, 15q13.3,
and a microduplication of 16p11.2 [22-25], with most
CNVs having a spectrum of pathologic features and
showing evidence of overlap with other forms of brain
disorder. Environmental factors that are associated with
an increased risk of developing schizophrenia include
exposure to stress in utero [26], low socioeconomic sta-
tus [27], urbanicity [28], and cannabis use [29].
Only a few genetic studies have been undertaken to
specifically identify genes leading to the development
and pathology of childhood-onset schizophrenia. Asso-
ciations have been reported with DAOA [30], NRG1
[31], DTNBP1 [32,33], and GAD1 [34]. Addington and
Rapoport [35] found that approximately 10% of child-
hood-onset schizophrenia patients in their cohort had
cytogenetic abnormalities, including deletions of 22q11,
atypical/mosaic 45,X and 47,XXX, recurrent duplications
of 16p11.2 and MYT1L (mapped to 2p25.3), and dele-
tion of NRXN1 (on 2p16.3), all of which have been
reported in adult-onset schizophrenia patients. Thus,
there appears to be considerable overlap of purported
candidate regions between adult and childhood-onset
schizophrenia, indicating the potential perturbation of
similar developmental pathways.
Here we report on a patient with onset schizophrenia
symptoms at age 5 years, and a subsequent diagnosis at
9 years of childhood-onset schizophrenia, attention defi-
cit hyperactivity disorder (ADHD) with hyperactivity
and impulsivity, and chronic motor tic disorder. Cytoge-
netic and molecular analyses demonstrate that this
patient carries an isodisomic isochromosome 13 of
paternal origin.
Case Presentation
The female patient presented to the study team at 9
years of age. Diagnoses were best estimate diagnoses
based on DSM-IV [1], determined after completion of a
semi-structured diagnostic interview of both the parents
and child [36]. Using a non-hierarchical diagnostic
approach, the subject met diagnostic criteria for schizo-
phrenia, attention deficit hyperactivity disorder (hyper-
activity/impulsivity subtype), and chronic motor tic
disorder. Pregnancy history was unremarkable, and
delivery was at term via planned caesarean section sec-
ondary to breach presentation. Early milestones were
delayed, and the patient underwent a developmental
evaluation at 2 1/2 year of age. Academically, the patient
has repeated grades and is currently in a special needs
program with some mainstreamed class time.
The patient first reported visual hallucinations at 5
years, and by 7 years psychotic symptoms included fre-
quent visual hallucinations, command auditory halluci-
nations, and grandiose beliefs about superhuman
powers. Patient symptoms described by the parents
included flat affect, periods of incoherence, and loosen-
ing of associations. All symptoms were present consis-
tently for 2 1/2 years prior to study enrollment. The
patient is under treatment with risperidone and amanta-
dine and is able to manage behavior during the day. Her
attention span is reported to be difficult but improved
with treatment. She still experiences auditory hallucina-
tions which are now ego dystonic and identifiable. In
addition, the patient has underdeveloped social skills
and has developed relapsing and remitting vocal tics, as
well as simple and complex motor tics.
Family history includes a maternal great grandmother
with recurrent psychiatric inpatient admissions, but
insufficient information was available for the study team
to clarify diagnosis. The patient’sm o t h e rh a dah i s t o r y
of depressive symptoms.
Results
Cytogenetics
Karyotypic analysis of twenty G-banded metaphases
from mitogen stimulated peripheral blood lymphocytes
was performed at the 450-650 band level. Analysis
revealed 45 chromosomes in each cell examined, with a
Robertsonian-type translocation of the long arms of
each homologue of chromosome 13 (Figures 1a and 1b).
The patient initially had a reported karyotype of 45,XX,
der(13;13)(q10;q10) which subsequently was modified to
45,XX,i(13)(q10) upon molecular characterization.
Fluorescence In Situ Hybridization (FISH)
Centromere status was determined by FISH analysis
with an alpha satellite probe homologous to the centro-
meric regions of chromosomes 13 and 21 (Figures 1c
and 1d) which showed the presence of a large, chromo-
some 13 centromere. This was interpreted as either two
centromeres separated by minimal or undetectable
short-arm material or as a single, large chromosome 13
centromere. Paternal and maternal cytogenetic analyses
revealed normal karyotypes.
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phrenia and deletions in chromosome 22q11.2 [37], this
region underwent examination in the patient and her
parents. FISH analysis in the DiGeorge/Velocardiofacial
syndrome critical region at chromosome 22q11.2 with
the DiGeorge/VCFS Tuple1 probe did not identify any
deletion or duplication in the patient or her parents in
this region on chromosome 22.
Simple tandem repeats
Because of the initial finding of the patient’s der(13;13)
(q10;q10), the chromosome 13 content of the patient
and her parents underwent characterization with twelve
simple tandem repeats (STRs) spanning chromosome 13
plus a control STR from chromosome 21. The patient
was homozygous for all chromosome 13 STRs (Table 1).
In six STRs, the patient had only paternal alleles, with
lack of detectable maternal alleles. Five of these STRs
were completely informative, the patient inheriting only
a single paternal allele when the father was heterozy-
gous. Based on these STRs, we were able to conclude
that the patient carried alleles from only a single pater-
nal chromosome 13, and thus had an isodisomic iso-
chromosome 13 accompanied by a karyotype of 45,XX,i
(13)(q10). The remaining six STRs of the twelve
examined were less informative, and while the patient
was homozygous at these STRs, the pattern was consis-
tent with either paternal or maternal inheritance.
Affymetrix Whole-Genome Human SNP 6.0 microarrays
In order to further refine the patient’s chromosome 13
status, DNA from the patient and her parents were uti-
lized for Affymetrix whole genome Human SNP 6.0
microarray evaluation. Allele analysis demonstrated that
the patient was homozygous for all of chromosome 13
(Figure 2). In contrast, both paternal and maternal DNA
demonstrated chromosome 13 heterozygosity. Chromo-
some 13 CNV status was examined, and the patient was
found to have minimal evidence of deletions or duplica-
tions [Additional File 1]. Of the nine regions of duplica-
tion/deletion that were identified on chromosome 13,
none reached default criteria required for identification
as a CNV segment (Minimum 100,000 bp or 50 markers
for gain/loss) with any degree of certainty. Five were not
located in any gene, and four were located in genes
(ATP8A2, LHFP, PHF11, RCBTB1,a n dPIBF1
(C13orf24)) not yet shown to be associated with schizo-
phrenia. Thus, of the five chromosome 13 genes with
evidence of duplication or deletion in the patient, none
appears to be candidates for her pathology. While not
Figure 1 Cytogenetic analysis of patient. A) 45,XX,i(13)(q10) chromosomal karyotype of proband, showing the presence of a single
metacentric chromosome consisting of two copies of the patient’s chromosome 13 joined at the centromere (arrow), B) Composite of derivative
13 homologues from three metaphase spreads with centromeres indicated by arrows, C) Composite of acrocentric homologues hybridized with
alpha satellite DNA probe for centromeres of chromosomes 13 and 21, demonstrating the presence of a large centromere on the
isochromosome 13, D) Interphase cell with alpha satellite DNA probe for centromeres of chromosomes 13 and 21. Arrow points to large likely
signal of the isochromosome 13.
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be investigated in future studies of this patient.
Several other regions of the genome associated with
CNVs in schizophrenia were examined, including chromo-
some 22 (Figure 3), which is implicated in childhood onset
schizophrenia [35], and chromosome 15 (Figure 4),
demonstrated to have copy number variations in patients
with schizophrenia [22]. While the patient and her mother
did have a small duplication on chromosome 22 (Figure
3), there was no evidence of deletions in the region impli-
cated in 22q11.2 Deletion Syndrome. The patient and her
father both had a deletion on chromosome 15 distal to the
CHRNA7 g e n e ,e n c o d i n gt h ea7* nicotinic receptor (Fig-
ure 4a). The patient’s mother had a chromosome 15 dupli-
cation of the CHRFAM7A gene (Figure 4b), which is also
associated with schizophrenia [38,39] and modulates a7*
nicotinic receptor activity [40,41]. While it is possible that
the patient’s prenatal environment contained perturba-
tions in nicotinic receptor activity, it seems unlikely that
chromosome 15 CNVs in this family can account for the
patient’s severe pathology. No CNVs were found in the
regions encoding NRXN1 and MYT1L on chromosome 2
[Additional file 2]. Analysis of chromosome 16p11.2 in
our patient reveals no significant regions of duplication or
deletion. However, the proband and her parents contain
regions of LOH on chromosome 16p11.2 [Additional file
3]. Since the patient’s chromosome 16 LOH is recapitu-
lated in her parents, it is unlikely to be involved in the
patient’sp a t h o l o g y .
Gene Analysis
Multiple genes encoded by chromosome 13 have been
suggested to contribute to schizophrenia susceptibility,
including DAOA [42], 5-HTR2A [43], KPNA3 and KPNB3
[44], ESD [45], ATXN8OS [46], KFL5 [47], EFNB2 [48],
and PCDH8 [49]. Since it was not possible to narrow
down the candidate region of chromosome 13, two genes
were chosen for sequence analysis based on their robust
association with schizophrenia: DAOA [42] and 5-HTR2A
[43]. Protein coding sequence from these two genes, along
with 300 bp of upstream non-coding sequence, 300 bp
downstream, and at least 25 bp into the splice junctions,
were sequenced in patient DNA and compared to canoni-
cal sequence (ensemble.org release 61). Five SNPs were
identified in the patient, two (rs6313 and rs6311) in 5-
HTR2A and three (rs1361562, rs2391191, and rs778294)
in DAOA [Additional file 4]. In all cases the patient was
homozygous for the detected polymorphism, consistent
with isodisomy. The patient’s father also was found to be
homozygous for the 5-HTR2A SNPs rs6313 and rs6311,
which are in linkage disequilibrium and are associated
with schizophrenia [43]. None of the polymorphisms iden-
tified in the patient was novel, and all had been previously
described (ensembl.org and ncbi.nlm.nih.gov). None of the
polymorphisms noted in the coding regions of either gene
was non-synonymous.
Conclusions
This report describes a patient with isochromosome 13,
accompanied by childhood-onset schizophrenia, ADHD
Table 1 STR analysis of patient and her parents
Marker Position Subject Genotype Inheritance
D13S175 1,653,855 Patient 1/1 Homozygous, P
Father 1/2
Mother 3/4
D13S171 14,064,951 Patient 1/1 Homozygous, M or P
Father 1/1
Mother 1/2
D13S218 19,831,225 Patient 1/1 Homozygous, M or P
Father 1/2
Mother 1/1
D13S155 34,882,886 Patient 1/1 Homozygous, M or P
Father 1/2
Mother 1/3
D13S176 41,205,385 Patient 1/1 Homozygous, P
Father 1/2
Mother 1/3
D13S71 75,575,535 Patient 1/1 Homozygous, P
Father 1/1
Mother 2/2
D13S154 76,860,260 Patient 1/1 Homozygous, P
Father 1/2
Mother 3/4
D13S174 102,954,076 Patient 1/1 Homozygous, M or P
Father 1/2
Mother 1/3
D13S1809 106,132,754 Patient 1/1 Homozygous, P
Father 1/2
Mother 2/3
D13S173 107,806,947 Patient 1/1 Homozygous, M or P
Father 1/2
Mother 1/1
D13S1265 109,328,688 Patient 1/1 Homozygous, P
Father 1/2
Mother 2/3
D13S1295 113,094,472 Patient 1/1 Homozygous, M or P
Father 1/2
Mother 1/1
D21S270 Patient 1/2
Father 1/2
Mother 2/3
Chromosome 13 and 21 markers, along with position on chromosome
(ensembl.org). Alleles were assigned arbitrary numbers, and genotype
information is given for the patient and parents. Inheritance patterns have
been determined. P indicates paternal inheritance and M indicates maternal
inheritance. Bolded inheritance patterns demonstrate the expression of a
single paternal allele and no maternal alleles in the patient, when the father is
heterozygous.
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tic disorder. Cytogenetic analysis revealed that the pro-
band carries a 45,XX,i(13)(q10) karyotype, and addi-
tional marker analysis demonstrated that the derivative
13 chromosome was a paternally derived isodisomic iso-
chromosome. Since the patient’s isochromosome 13 had
no evidence of recombination, it most likely formed
post-zygotically by monosomy rescue [50]. However, we
cannot rule out the possibility that the proband’sf a t h e r
i sam o s a i cc a r r i e ro ft h ei s o c h r o m o s o m e1 3 .U n l e s s
associated with trisomy 13, cases of isochromosome 13
typically do not lead to pathology, although the long-
term follow-up needed for detection of mental illness
has not typically been reported [51-53]. There are sev-
eral potential mechanisms by which the proband’si s o -
chromosome 13 could lead to the observed pathology.
We were able to examine two of these: reduction to
homozygosity of a paternal mutation and reduction to
homozygosity of a paternal CNV. The failure to demon-
strate either of these leads us to consider whether alter-
native mechanisms, such as epigenetic regulation, may
be responsible for the patient’s features.
We initially hypothesized that the patient’s father was
a heterozygous carrier of a mutation on chromosome 13
that could lead to a phenotype when homozygous in the
patient. No overtly pathogenic mutations were detected,
although the patient and her father were shown to be
homozygous carriers of 5-HTR2A polymorphisms asso-
ciated with predisposition to schizophrenia (discussed
below). We also examined whether the patient exhibited
a reduction to homozygosity of a heterozygous chromo-
some 13 paternal CNV. While several of these small
Figure 2 Chromosome 13 Affymetrix Whole-Genome Human SNP 6.0 analysis. Allele analysis demonstrates complete homozygosity of the
patient’s chromosome 13, with an absence of heterozygous alleles. The patient’s parents have both homozygous and heterozygous alleles.
Heterozygous markers lie along the center line, while homozygous markers fall either above or below the line.
Figure 3 Chromosome 22 Affymetrix Whole-Genome Human SNP 6.0 analysis. The 1.5 Mb region of chromosome 22 associated with
22q11.2 Deletion Syndrome in schizophrenia [85] is noted by a box. The patient and her mother both contain a small duplication at the
centromeric end of the 22q11.2 deletion syndrome region, but neither has a deletion.
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Figure 4 Chromosome 15 Affymetrix Whole-Genome Human SNP 6.0 analysis. A) Copy number analysis flanking CHRNA7 gene, with
downward arrows indicating a deleted region in the patient and father just distal to CHRNA7 and upward arrows indicating the beginning of a
duplicated region in mother. B) Copy number analysis flanking CHRFAM7A gene, with arrows indicating the beginning and the end of the
duplicated region in the patient’s mother.
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is known to be associated with schizophrenia. Thus,
chromosome 13 CNVs do not appear to be a robust
candidate for her pathology.
We investigated other non-chromosome 13 CNVs and
cytogenetic abnormalities. Childhood-onset schizophre-
nia abnormalities identified by Addington and Rapoport
[35] include 22q11, 45,X atypical/mosaic, 47,XXX, dupli-
cations of 16p11.2, MYT1L duplication on chromosome
2, and NRXN1 deletion on chromosome 2. Affymetrix
SNP analysis and standard cytogenetics allow us to con-
clude that this patient has no evidence of the pathologic
alterations described by Addington and Rapoport. Simi-
larly, while there was evidence of CNVs on chromosome
15 in the regions associated with schizophrenia, it seems
unlikely that chromosome 15 CNVs can account for her
severe pathology.
Schizophrenia has been reported in several patients
with chromosome 13 rearrangements, and these cases
illustrate the difficulty in establishing a causal rather
than coincidental relationship between the cytogenetic
abnormality and psychiatric pathology. Roberts and
coworkers [54] reported an inversion/insertion involving
chromosome 13, with breakpoints at 13q21.3, 13q32,
and 13q31, and although the abnormality was found in
several family members with “mental subnormality, per-
sonality defects and frank psychosis,” concordance was
not 100%. In this case, pathology may be the result of
breakpoint disruption of genes on chromosome 13. Ito-
kawa and coworkers [55] reported a karyotype of 46,XY,
t(4;13)(p16.1;q21.31) in a single patient with a diagnosis
of paranoid schizophrenia, and pathology may be asso-
ciated with disruption of genes on either chromosome 4
or 13. In contrast, schizophrenia in patients with
balanced t(13;14), which are common and heterologous,
has been reported [56-58], and it is likely that the occur-
rence of both a chromosome translocation and psychia-
tric pathology in these patients is coincidental. Thus,
while chromosome 13 abnormalities have been found in
patients with schizophrenia, it has proven difficult to
demonstrate unambiguously that the chromosome
abnormality leads to the pathology.
The results presented here lead us to question
whether the patient’s isochromosome 13 directly leads
to her symptoms or is a coincidental finding. Isochro-
mosome 13 is rare [59] and the occurrence of both i
(13)(q10) and childhood onset schizophrenia in a sin-
gle individual would be extremely unlikely. While we
have investigated two potential mechanisms by which i
(13)(q10) could lead to the patient’s pathology, our
investigations have not been exhaustive. Mutations in
chromosome 13 genes not studied, or in parts of 5-
HTR2A or DAOA not sequenced here, may be
pathogenic.
There are also additional mechanisms that may be
considered. For example, there has been intense specula-
tion concerning the role of epigenetic modification in
the susceptibility and development of schizophrenia
[60-64]. In cases where the origins have been deter-
mined, both maternally and paternally derived uniparen-
tal disomy (UPD) of chromosome 13 have been
associated with normal development [51-53]. In many
cases, however, follow-up has not been extended past
childhood, so the possibility of later development of psy-
chiatric pathology cannot be ruled out. There is evi-
dence that regions of chromosome 13 are imprinted in
an individual, tissue-specific, or polymorphic fashion,
and that regulation may be complex. For example, stu-
dies demonstrate allele-specific and parent-of-origin-
specific differential expression of 5-HTR2A [65-71] and
Abdolmaleky and coworkers [72] have found evidence
for differences between epigenetic regulation of 5-
HTR2A between patients with schizophrenia or bipolar
disorder and controls.
There is precedence for the co-occurrence of unipar-
ental disomy (UPD) and childhood-onset schizophrenia.
Seal and coworkers [73] reported a case of childhood-
onset schizophrenia associated with segmental UPD of
chromosome 5q32-qter. Linkage of schizophrenia to
chromosome 5p23.2-p24 has been previously described
by multiple groups [74-80], and several candidate genes
have been proposed, including the GABA receptor
genes, EPN4 [81], SMAD5, and SPRY4 [82].
The patient described here exhibits childhood-onset
schizophrenia, ADHD, and chronic motor tic disorder
accompanied by the karyotype 45,XX,i(13)(q10q10).
Although we did not find ove r t l yp a t h o g e n i cc h r o m o -
some 13 CNVs or mutations in the patient, there may be
unidentified mutations in regions of chromosome 13 that
were not examined. We did demonstrate that the patient
and her father are homozygous carriers of 5-HTR2A
SNPs associated with schizophrenia. Considering the
complete homozygosity and UPD of the patient’sc h r o -
mosome 13, epigenetic modifications should be investi-
gated as a potential explanation for the patient’s findings.
Methods
Patient Recruitment
The patient originally was identified requiring treatment
for psychosis, and patient and family material and infor-
mation were collected as part of an ongoing study which
includes cytogenetic analysis of children with psychotic
symptoms. Informed consent and assent were obtained
as monitored by a local Institutional Review Board.
Cytogenetics
Cytogenetic analysis of peripheral blood lymphocytes
was conducted by the Colorado Genetics Laboratory
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10% fetal bovine serum, cultures were exposed to a final
concentration of 0.06 micrograms/mL of Colcemid
(Irvine Scientific, Santa Ana, CA) for 30 min - 2 hr in
order to capture metaphase cells. Cells were exposed to
0.075 M KCl hypotonic for 30 min and fixed in 3:1
methanol:glacial acetic acid. Trypsin G-banding was per-
formed following standard procedures [83].
Fluorescence in situ hybridization (FISH)
FISH analysis utilized an alpha satellite probe with
homology to the centromeric heterochromatic regions
of chromosomes 13 and 21. FISH analysis for the
DiGeorge/Velocardiofacial syndrome (VCSF) critical
region at chromosome 22q11.2 was performed with the
DiGeorge/VCFS Tuple1 probe using standard methods
(Abbott Molecular, Abbott Park, Illinois).
Simple Tandem Repeats (STRs)
Polymerase Chain Reaction was performed with Taq
Gold (Applied Biosystems, Foster City, CA) using pri-
mers designed from UniSTS http://ncbi.nlm.nih.gov/
unists on a GeneAmp 9700 thermal cycler (Applied Bio-
systems, Inc., Foster City, CA). Products were analyzed
on an Applied Biosystem’s 3100 Avant Genetic Analy-
zer, and results interpreted with GeneMapper version
3.5 (Applied Biosystem, Inc.). DNA was purified by phe-
nol extraction from lymphoblasts using standard proto-
cols [84].
Affymetrix GenomeWide 6.0 SNP microarrays
The Affymetrix Genome-Wide Human SNP 6.0 assay
was performed according to the manufacturer’s instruc-
tions (Affymetrix, Santa Clara, CA) in the Genomics
and Microarray Core Laboratory at the University of
Colorado School of Medicine. Data were combined with
HapMap samples provided by Affymetrix and analyzed
using the Affymetric Genotyping Console version 4.0.
Algorithms for copy number calling are based on the
Hidden-Markoff Model, where copy number patterns of
neighboring markers are taken into account.
Gene Sequence Analysis
Genomic sequences and intron/exon structure for D-
amino acid oxidase activator (DAOA;
ENSG00000192346) and 5-hydroxytryptamine (seroto-
nin) receptor 2A (5-HTR2A; ENSG00000102468) were
taken from Ensembl Release 61 - Feb 2011 and earlier
releases http://ensembl.org, and were used to generate
primers for PCR and sequencing with the program Pri-
mer3 http://frodo.wi.mit.edu/. Products were sequenced
directly without additional purification using the Big-
Dye
® Terminator v3.1 Cycle Sequence Kit (Applied Bio-
systems, Austin, TX) on an ABI 3100-Avant Genetic
Analyzer (Applied Biosystems, Inc.), and analyzed with
Sequencher 4.8 (Gene Codes Corporation, Ann Arbor
MI). Subject sequences were compared to database
sequences using Basic Local Alignment Search Tool
(BLAST) http://www.ncbi.nlm.nih.gov/BLAST/.
Consent
Written informed consent was obtained from the
patient’s parents for publication of this Case Report. A
copy of the written consent is available for review by
the Editor-in-Chief of this journal.
Additional material
Additional file 1: Chromosome 13 CNV analysis of patient and
father. CNV analysis indicates the presence of two copies of almost all
chromosome 13 markers in the patient and her father.
Additional file 2: Affymetrix Whole-Genome Human SNP6.0 CNV
analysis of MYT1L and NRXN1 genes. Analysis indicates that the
patient and her parents have two copies of the MYT1L and NRXN1 genes.
Additional file 3: Affymetrix Whole-genome Human SNP6.0 analysis
of chromosome 16. Analysis indicates that the patient and her parents
have regions on chromosome 16 with reduced heterozygosity, and that
no significant deletions or duplications are found.
Additional file 4: SNP analysis. SNPS were detected in DAOA and
HTR2A genes of patient.
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(RCC1) and BTB (POZ) domain contain protein 1; SMAD5: mothers against
decapentaplegic, drosophila, homolog of, 5; SNP: single nucleotide
polymorphism; SPRY4: sprout, drosophila, homolog of, 4; STR: simple tandem
repeat; UPD: uniparental disomy; UTR: untranslated region; VCFS:
velocardiofacial syndrome; ZNF804A: zinc finger protein 804A
Acknowledgements
We would like to thank Robert Freedman for his helpful suggestions and
critical reading of this manuscript. This work was supported by NIH grants
MH081177 and DA09457, and the Veterans Affairs Medical Research Service.
Author details
1Department of Psychiatry, University of Colorado School of Medicine,
Aurora, CO, USA.
2Colorado Genetics Laboratory, Department of Pathology,
University of Colorado School of Medicine, Aurora, CO, USA.
3Department of
Psychiatry and Behavioral Science, Children’s Hospital Colorado, Aurora, CO,
Graw et al. Molecular Cytogenetics 2012, 5:2
http://www.molecularcytogenetics.org/content/5/1/2
Page 8 of 11USA.
4Research Division, Veterans Affairs Medical Research Service, Denver,
CO, USA.
Authors’ contributions
SG conceived of the study and its design, performed the sequencing, and
analyzed the data, and wrote the manuscript. KS supervised the cytogenetic
analysis. KF performed the STR analysis. BJC performed the cytogenetic
analysis. MZW and RGR examined the patient and provided clinical details.
SL participated in study design and data analysis. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 August 2011 Accepted: 3 January 2012
Published: 3 January 2012
References
1. American Psychiatric Association: Diagnostic and statistical manual of mental
disorders Washington, D.C.; 1994.
2. Cannon M, Jones P, Huttunen MO, Tanskanen A, Huttunen T, Rabe-
Hesketh S, Murray RM: School performance in Finnish children and later
development of schizophrenia: a population-based longitudinal study.
Arch Gen Psychiatry 1999, 56:457-463.
3. Ross RG, Olincy A, Harris JG, Radant A, Hawkins M, Adler LE, Freedman R:
Evidence for bilineal inheritance of physiological indicators of risk in
childhood-onset schizophrenia. Am J Med Genet 1999, 88:188-199.
4. Kyriakopoulos M, Frangou S: Pathophysiology of early onset
schizophrenia. Int Rev Psychiatry 2007, 19:315-324.
5. Leonard S, Freedman R: Genetics of chromosome 15q13-q14 in
schizophrenia. Biol Psychiatry 2006, 60:115-122.
6. Muller DJ, Zai CC, Shinkai T, Strauss J, Kennedy JL: Association between
the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar
disorder and schizophrenia. Bipolar Disord 2011, 13:198-207.
7. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and
neuropathology: on the matter of their convergence. Mol Psychiatry 2005,
10:40-68.
8. Athanasiu L, Mattingsdal M, Kahler AK, Brown A, Gustafsson O, Agartz I,
Giegling I, Muglia P, Cichon S, Rietschel M, Pietilainen OP, Peltonen L,
Bramon E, Collier D, Clair DS, Sigurdsson E, Petursson H, Rujescu D, Melle I,
Steen VM, Djurovic S, Andreassen OA: Gene variants associated with
schizophrenia in a Norwegian genome-wide study are replicated in a
large European cohort. J Psychiatr Res 2010, 44:748-753.
9. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF,
Sklar P: Common polygenic variation contributes to risk of schizophrenia
and bipolar disorder. Nature 2009, 460:748-752.
10. Kirov G, Zaharieva I, Georgieva L, Moskvina V, Nikolov I, Cichon S, Hillmer A,
Toncheva D, Owen MJ, O’Donovan MC: A genome-wide association study
in 574 schizophrenia trios using DNA pooling. Mol Psychiatry 2009,
14:796-803.
11. Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM,
Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal
cytokine receptor gene locus in schizophrenia. Mol Psychiatry 2007,
12:572-580.
12. Liu Y, Chen G, Norton N, Liu W, Zhu H, Zhou P, Luan M, Yang S, Chen X,
Carroll L, Williams NM, O’Donovan MC, Kirov G, Owen MJ: Whole genome
association study in a homogenous population in Shandong peninsula
of China reveals JARID2 as a susceptibility gene for schizophrenia. J
Biomed Biotechnol 2009, 2009:536918.
13. Mah S, Nelson MR, Delisi LE, Reneland RH, Markward N, James MR,
Nyholt DR, Hayward N, Handoko H, Mowry B, Kammerer S, Braun A:
Identification of the semaphorin receptor PLXNA2 as a candidate for
susceptibility to schizophrenia. Mol Psychiatry 2006, 11:471-478.
14. Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W,
Kasperaviciute D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G,
Jayathilake K, Cola PA, McEvoy JP, Keefe RS, Fisher EM, St Jean PL,
Giegling I, Hartmann AM, Moller HJ, Ruppert A, Fraser G, Crombie C,
Middleton LT, St CD, Roses AD, Muglia P, Francks C, et al: A genome-wide
investigation of SNPs and CNVs in schizophrenia. PLoS Genet 2009, 5:
e1000373.
15. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, Dudbridge F,
Holmans PA, Whittemore AS, Mowry BJ, Olincy A, Amin F, Cloninger CR,
Silverman JM, Buccola NG, Byerley WF, Black DW, Crowe RR, Oksenberg JR,
Mirel DB, Kendler KS, Freedman R, Gejman PV: Common variants on
chromosome 6p22.1 are associated with schizophrenia. Nature 2009,
460:753-757.
16. Shifman S, Johannesson M, Bronstein M, Chen SX, Collier DA, Craddock NJ,
Kendler KS, Li T, O’Donovan M, O’Neill FA, Owen MJ, Walsh D,
Weinberger DR, Sun C, Flint J, Darvasi A: Genome-wide association
identifies a common variant in the reelin gene that increases the risk of
schizophrenia only in women. PLoS Genet 2008, 4:e28.
17. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D,
Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O,
Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J,
Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A,
Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J,
Breuer R, Moller HJ, Giegling I, et al: Common variants conferring risk of
schizophrenia. Nature 2009, 460:744-747.
18. Sullivan PF: The psychiatric GWAS consortium: big science comes to
psychiatry. Neuron 2010, 68:182-186.
19. O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V,
Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P,
Marchini JL, Spencer CC, Howie B, Leung HT, Hartmann AM, Moller HJ,
Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W,
Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, et al:
Identification of loci associated with schizophrenia by genome-wide
association and follow-up. Nat Genet 2008, 40:1053-1055.
20. Potkin SG, Turner JA, Guffanti G, Lakatos A, Fallon JH, Nguyen DD,
Mathalon D, Ford J, Lauriello J, Macciardi F: A genome-wide association
study of schizophrenia using brain activation as a quantitative
phenotype. Schizophr Bull 2009, 35:96-108.
21. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY,
Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St CD, Corvin A,
Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK,
Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D,
Ruderfer DM, Fanous A, Stefansson H, Steinberg S, et al: Genome-wide
association study identifies five new schizophrenia loci. Nat Genet 2011,
43:969-976.
22. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S,
Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T,
Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A,
Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A,
Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T,
Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, et al:
Large recurrent microdeletions associated with schizophrenia. Nature
2008, 455:232-236.
23. McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S,
Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA,
Grozeva D, Malhotra D, Walsh T, Zackai EH, Kaplan P, Ganesh J, Krantz ID,
Spinner NB, Roccanova P, Bhandari A, Pavon K, Lakshmi B, Leotta A,
Kendall J, Lee YH, Vacic V, Gary S, Iakoucheva LM, et al: Microduplications
of 16p11.2 are associated with schizophrenia. Nat Genet 2009,
41:1223-1227.
24. Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, Zhang N, Mowry BJ,
Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF,
Black DW, Kendler KS, Freedman R, Dudbridge F, Pe’er I, Hakonarson H,
Bergen SE, Fanous AH, Holmans PA, Gejman PV: Copy number variants in
schizophrenia: confirmation of five previous findings and new evidence
for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry 2011,
168:302-316.
25. International Schizophrenia Consortium: Rare chromosomal deletions and
duplications increase risk of schizophrenia. Nature 2008, 455:237-241.
26. Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of
epidemiologic and translational studies. Am J Psychiatry 2010,
167:261-280.
27. Wicks S, Hjern A, Dalman C: Social risk or genetic liability for psychosis? A
study of children born in Sweden and reared by adoptive parents. Am J
Psychiatry 2010, 167:1240-1246.
28. Dragt S, Nieman DH, Veltman D, Becker HE, van de Fliert R, de HL,
Linszen DH: Environmental factors and social adjustment as predictors of
Graw et al. Molecular Cytogenetics 2012, 5:2
http://www.molecularcytogenetics.org/content/5/1/2
Page 9 of 11a first psychosis in subjects at ultra high risk. Schizophr Res 2011,
125:69-76.
29. Andreasson S, Allebeck P, Engstrom A, Rydberg U: Cannabis and
schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987,
2:1483-1486.
30. Yue W, Liu Z, Kang G, Yan J, Tang F, Ruan Y, Zhang J, Zhang D: Association
of G72/G30 polymorphisms with early-onset and male schizophrenia.
Neuroreport 2006, 17:1899-1902.
31. Addington AM, Gornick MC, Shaw P, Seal J, Gogtay N, Greenstein D,
Clasen L, Coffey M, Gochman P, Long R, Rapoport JL: Neuregulin 1 (8p12)
and childhood-onset schizophrenia: susceptibility haplotypes for
diagnosis and brain developmental trajectories. Mol Psychiatry 2007,
12:195-205.
32. Gornick MC, Addington AM, Sporn A, Gogtay N, Greenstein D, Lenane M,
Gochman P, Ordonez A, Balkissoon R, Vakkalanka R, Weinberger DR,
Rapoport JL, Straub RE: Dysbindin (DTNBP1, 6p22.3) is associated with
childhood-onset psychosis and endophenotypes measured by the
Premorbid Adjustment Scale (PAS). J Autism Dev Disord 2005, 35:831-838.
33. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-
Kerr C, Wormley B, Sadek H, Kadambi B, Cesare AJ, Gibberman A, Wang X,
O’Neill FA, Walsh D, Kendler KS: Genetic variation in the 6p22.3 gene
DTNBP1, the human ortholog of the mouse dysbindin gene, is
associated with schizophrenia. Am J Hum Genet 2002, 71:337-348.
34. Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A,
Greenstein D, Lenane M, Gochman P, Baker N, Balkissoon R, Vakkalanka RK,
Weinberger DR, Rapoport JL, Straub RE: GAD1 (2q31.1), which encodes
glutamic acid decarboxylase (GAD67), is associated with childhood-
onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry
2005, 10:581-588.
35. Addington AM, Rapoport JL: The genetics of childhood-onset
schizophrenia: when madness strikes the prepubescent. Curr Psychiatry
Rep 2009, 11:156-161.
36. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D,
Ryan N: Schedule for Affective Disorders and Schizophrenia for School-
Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability
and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36:980-988.
37. Bassett AS, Chow EW: Schizophrenia and 22q11.2 deletion syndrome.
Curr Psychiatry Rep 2008, 10:148-157.
38. Flomen RH, Collier DA, Osborne S, Munro J, Breen G, St CD, Makoff AJ:
Association study of CHRFAM7A copy number and 2 bp deletion
polymorphisms with schizophrenia and bipolar affective disorder. Am J
Med Genet B Neuropsychiatr Genet 2006, , 141B: 571-575.
39. Sinkus ML, Lee MJ, Gault J, Logel J, Short M, Freedman R, Christian SL,
Lyon J, Leonard S: A 2-base pair deletion polymorphism in the partial
duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on
chromosome 15q14 is associated with schizophrenia. Brain Res 2009,
1291:1-11.
40. Araud T, Graw S, Berger R, Lee M, Neveu E, Bertrand D, Leonard S: The
chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is
a dominant negative regulator of alpha7*nAChR function. Biochem
Pharmacol 2011, 82:904-914.
41. de Lucas-Cerrillo AM, Maldifassi MC, Arnalich F, Renart J, Atienza G,
Serantes R, Cruces J, Sanchez-Pacheco A, Andres-Mateos E, Montiel C:
Function of partially duplicated human alpha77 nicotinic receptor
subunit CHRFAM7A gene: potential implications for the cholinergic anti-
inflammatory response. J Biol Chem 2011, 286:594-606.
42. Addington AM, Gornick M, Sporn AL, Gogtay N, Greenstein D, Lenane M,
Gochman P, Baker N, Balkissoon R, Vakkalanka RK, Weinberger DR,
Straub RE, Rapoport JL: Polymorphisms in the 13q33.2 gene G72/G30 are
associated with childhood-onset schizophrenia and psychosis not
otherwise specified. Biol Psychiatry 2004, 55:976-980.
43. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT: Meta-analysis of
association between the T102C polymorphism of the 5HT2a receptor
gene and schizophrenia. Schizophr Res 2004, 67:53-62.
44. Zhang H, Ju G, Wei J, Hu Y, Liu L, Xu Q, Chen Y, Sun Z, Liu S, Yu Y, Guo Y,
Shen Y: A combined effect of the KPNA3 and KPNB3 genes on
susceptibility to schizophrenia. Neurosci Lett 2006, 402:173-175.
45. Fananas L, Moral P, Marti Tusquets JL, Bertranpetit J: Genetic markers in
schizophrenia: ACP1, ESD, TF and GC polymorphisms. Hum Hered 1990,
40:136-140.
46. Vincent JB, Yuan QP, Schalling M, Adolfsson R, Azevedo MH, Macedo A,
Bauer A, DallaTorre C, Medeiros HM, Pato MT, Pato CN, Bowen T, Guy CA,
Owen MJ, O’Donovan MC, Paterson AD, Petronis A, Kennedy JL: Long
repeat tracts at SCA8 in major psychosis. Am J Med Genet 2000,
96:873-876.
47. Yanagi M, Hashimoto T, Kitamura N, Fukutake M, Komure O, Nishiguchi N,
Kawamata T, Maeda K, Shirakawa O: Expression of Kruppel-like factor 5
gene in human brain and association of the gene with the susceptibility
to schizophrenia. Schizophr Res 2008, 100:291-301.
48. Zhang R, Zhong NN, Liu XG, Yan H, Qiu C, Han Y, Wang W, Hou WK, Liu Y,
Gao CG, Guo TW, Lu SM, Deng HW, Ma J: Is the EFNB2 locus associated
with schizophrenia? Single nucleotide polymorphisms and haplotypes
analysis. Psychiatry Res 2010, 180:5-9.
49. Bray NJ, Kirov G, Owen RJ, Jacobsen NJ, Georgieva L, Williams HJ, Norton N,
Spurlock G, Jones S, Zammit S, O’Donovan MC, Owen MJ: Screening the
human protocadherin 8 (PCDH8) gene in schizophrenia. Genes Brain
Behav 2002, 1:187-191.
50. Shaffer LG, Lupski JR: Molecular mechanisms for constitutional
chromosomal rearrangements in humans. Annu Rev Genet 2000,
34:297-329.
51. Berend SA, Feldman GL, McCaskill C, Czarnecki P, Van Dyke DL, Shaffer LG:
Investigation of two cases of paternal disomy 13 suggests timing of
isochromosome formation and mechanisms leading to uniparental
disomy. Am J Med Genet 1999, 82:275-281.
52. Soler A, Margarit E, Queralt R, Carrio A, Costa D, Gomez D, Ballesta F:
Paternal isodisomy 13 in a normal newborn infant after trisomy rescue
evidenced by prenatal diagnosis. Am J Med Genet 2000, 90:291-293.
53. Slater H, Shaw JH, Dawson G, Bankier A, Forrest SM: Maternal uniparental
disomy of chromosome 13 in a phenotypically normal child. J Med Genet
1994, 31:644-646.
54. Roberts SH, Cowie VA, Singh KR: Intrachromosomal insertion of
chromosome 13 in a family with psychosis and mental subnormality. J
Ment Defic Res 1986, 30(Pt 3):227-232.
55. Itokawa M, Kasuga T, Yoshikawa T, Matsushita M: Identification of a male
schizophrenic patient carrying a de novo balanced translocation, t(4; 13)
(p16.1; q21.31). Psychiatry Clin Neurosci 2004, 58:333-337.
56. Escobar JI: A cytogenetic study of children with psychiatric disorders.
Compr Psychiatry 1976, 17:309-313.
57. Price WH, Brunton M, Buckton K, Jacobs PA: Chromosome survey of new
patients admitted to the four maximum security hospitals in the United
Kingdom. Clin Genet 1976, 9:389-398.
58. Macintyre DJ, Blackwood DH, Porteous DJ, Pickard BS, Muir WJ:
Chromosomal abnormalities and mental illness. Mol Psychiatry 2003,
8:275-287.
59. Chen CP, Chern SR, Wu PC, Tsai FJ, Lee CC, Town DD, Chen WL, Chen LF,
Lee MS, Pan CW, Wang W: Unbalanced and balanced acrocentric
rearrangements involving chromosomes other than chromosome 21 at
amniocentesis. Taiwan J Obstet Gynecol 2009, 48:389-399.
60. Pidsley R, Mill J: Epigenetic studies of psychosis: current findings,
methodological approaches, and implications for postmortem research.
Biol Psychiatry 2011, 69:146-156.
61. Perrin M, Kleinhaus K, Messinger J, Malaspina D: Critical periods and the
developmental origins of disease: an epigenetic perspective of
schizophrenia. Ann N Y Acad Sci 2010, , 1204 Suppl: E8-13.
62. Brown AS: The environment and susceptibility to schizophrenia. Prog
Neurobiol 2011, 93:23-58.
63. Akbarian S: Epigenetics of schizophrenia. Curr Top Behav Neurosci 2010,
4:611-628.
64. Lester BM, Tronick E, Nestler E, Abel T, Kosofsky B, Kuzawa CW, Marsit CJ,
Maze I, Meaney MJ, Monteggia LM, Reul JM, Skuse DH, Sweatt JD,
Wood MA: Behavioral epigenetics. Ann N Y Acad Sci 2011, 1226:14-33.
65. Bunzel R, Blumcke I, Cichon S, Normann S, Schramm J, Propping P,
Nothen MM: Polymorphic imprinting of the serotonin-2A (5-HT2A)
receptor gene in human adult brain. Brain Res Mol Brain Res 1998,
59:90-92.
66. Kato MV, Shimizu T, Nagayoshi M, Kaneko A, Sasaki MS, Ikawa Y: Genomic
imprinting of the human serotonin-receptor (HTR2) gene involved in
development of retinoblastoma. Am J Hum Genet 1996, 59:1084-1090.
67. Kato MV, Ikawa Y, Hayashizaki Y, Shibata H: Paternal imprinting of mouse
serotonin receptor 2A gene Htr2 in embryonic eye: a conserved
imprinting regulation on the RB/Rb locus. Genomics 1998, 47:146-148.
Graw et al. Molecular Cytogenetics 2012, 5:2
http://www.molecularcytogenetics.org/content/5/1/2
Page 10 of 1168. Fukuda Y, Koga M, Arai M, Noguchi E, Ohtsuki T, Horiuchi Y, Ishiguro H,
Niizato K, Iritani S, Itokawa M, Arinami T: Monoallelic and unequal allelic
expression of the HTR2A gene in human brain and peripheral
lymphocytes. Biol Psychiatry 2006, 60:1331-1335.
69. Bray NJ, Buckland PR, Hall H, Owen MJ, O’Donovan MC: The serotonin-2A
receptor gene locus does not contain common polymorphism affecting
mRNA levels in adult brain. Mol Psychiatry 2004, 9:109-114.
70. Polesskaya OO, Aston C, Sokolov BP: Allele C-specific methylation of the
5-HT2A receptor gene: evidence for correlation with its expression and
expression of DNA methylase DNMT1. J Neurosci Res 2006, 83:362-373.
71. Polesskaya OO, Sokolov BP: Differential expression of the “C” and “T”
alleles of the 5-HT2A receptor gene in the temporal cortex of normal
individuals and schizophrenics. J Neurosci Res 2002, 67:812-822.
72. Abdolmaleky HM, Yaqubi S, Papageorgis P, Lambert AW, Ozturk S,
Sivaraman V, Thiagalingam S: Epigenetic dysregulation of HTR2A in the
brain of patients with schizophrenia and bipolar disorder. Schizophr Res
2011, 129:183-190.
73. Seal JL, Gornick MC, Gogtay N, Shaw P, Greenstein DK, Coffey M,
Gochman PA, Stromberg T, Chen Z, Merriman B, Nelson SF, Brooks J,
Arepalli S, Wavrant-De VF, Hardy J, Rapoport JL, Addington AM: Segmental
uniparental isodisomy on 5q32-qter in a patient with childhood-onset
schizophrenia. J Med Genet 2006, 43:887-892.
74. Straub RE, MacLean CJ, O’Neill FA, Walsh D, Kendler KS: Support for a
possible schizophrenia vulnerability locus in region 5q22-31 in Irish
families. Mol Psychiatry 1997, 2:148-155.
75. Lewis CM, Levinson DF, Wise LH, Delisi LE, Straub RE, Hovatta I,
Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM,
Kaufmann CA, Garver DL, Gurling HM, Lindholm E, Coon H, Moises HW,
Byerley W, Shaw SH, Mesen A, Sherrington R, O’Neill FA, Walsh D,
Kendler KS, Ekelund J, Paunio T, Lonnqvist J, Peltonen L, O’Donovan MC,
Owen MJ, et al: Genome scan meta-analysis of schizophrenia and bipolar
disorder, part II: Schizophrenia. Am J Hum Genet 2003, 73:34-48.
76. Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sherrington R,
Mankoo BS, Read T, Murphy P, Blaveri E, McQuillin A, Petursson H, Curtis D:
Genomewide genetic linkage analysis confirms the presence of
susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2,
and 8p21-22 and provides support for linkage to schizophrenia, on
chromosomes 11q23.3-24 and 20q12.1-11.23. Am J Hum Genet 2001,
68:661-673.
77. Schwab SG, Eckstein GN, Hallmayer J, Lerer B, Albus M, Borrmann M,
Lichtermann D, Ertl MA, Maier W, Wildenauer DB: Evidence suggestive of a
locus on chromosome 5q31 contributing to susceptibility for
schizophrenia in German and Israeli families by multipoint affected sib-
pair linkage analysis. Mol Psychiatry 1997, 2:156-160.
78. Paunio T, Ekelund J, Varilo T, Parker A, Hovatta I, Turunen JA, Rinard K,
Foti A, Terwilliger JD, Juvonen H, Suvisaari J, Arajarvi R, Suokas J,
Partonen T, Lonnqvist J, Meyer J, Peltonen L: Genome-wide scan in a
nationwide study sample of schizophrenia families in Finland reveals
susceptibility loci on chromosomes 2q and 5q. Hum Mol Genet 2001,
10:3037-3048.
79. Devlin B, Bacanu SA, Roeder K, Reimherr F, Wender P, Galke B, Novasad D,
Chu A, TCuenco K, Tiobek S, Otto C, Byerley W: Genome-wide multipoint
linkage analyses of multiplex schizophrenia pedigrees from the oceanic
nation of Palau. Mol Psychiatry 2002, 7:689-694.
80. Sklar P, Pato MT, Kirby A, Petryshen TL, Medeiros H, Carvalho C, Macedo A,
Dourado A, Coelho I, Valente J, Soares MJ, Ferreira CP, Lei M, Verner A,
Hudson TJ, Morley CP, Kennedy JL, Azevedo MH, Lander E, Daly MJ,
Pato CN: Genome-wide scan in Portuguese Island families identifies
5q31-5q35 as a susceptibility locus for schizophrenia and psychosis. Mol
Psychiatry 2004, 9:213-218.
81. Pimm J, McQuillin A, Thirumalai S, Lawrence J, Quested D, Bass N, Lamb G,
Moorey H, Datta SR, Kalsi G, Badacsonyi A, Kelly K, Morgan J, Punukollu B,
Curtis D, Gurling H: The Epsin 4 gene on chromosome 5q, which
encodes the clathrin-associated protein enthoprotin, is involved in the
genetic susceptibility to schizophrenia. Am J Hum Genet 2005, 76:902-907.
82. Zaharieva I, Georgieva L, Nikolov I, Kirov G, Owen MJ, O’Donovan MC,
Toncheva D: Association study in the 5q31-32 linkage region for
schizophrenia using pooled DNA genotyping. BMC Psychiatry 2008, 8:11.
83. Gustashaw KM: Chromosome stains. In The AGT cytogenetic laboratory
manual.. 3 edition. Edited by: Barch,MJ, Knutsen, T., and Spurbeck, J. L.
Philadelphia: Lippincott-Raven; 1997:269-280.
84. Sambrook J, Russell DW: Molecular Cloning A Laboratory Manual Cold Spring
Harbor, New York: Cold Spring Harbor Laboratory Press; 2001.
85. Karayiorgou M, Simon TJ, Gogos JA: 22q11.2 microdeletions: linking DNA
structural variation to brain dysfunction and schizophrenia. Nat Rev
Neurosci 2010, 11:402-416.
doi:10.1186/1755-8166-5-2
Cite this article as: Graw et al.: Isochromosome 13 in a patient with
childhood-onset schizophrenia, ADHD, and motor tic disorder. Molecular
Cytogenetics 2012 5:2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Graw et al. Molecular Cytogenetics 2012, 5:2
http://www.molecularcytogenetics.org/content/5/1/2
Page 11 of 11